Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
Top Stocks to Buy with Rising EPS Estimates After Earnings
by Shaun Pruitt
These companies saw their stocks spike after impressively beating earnings expectations last week and more upside could be ahead considering EPS estimates for fiscal 2024 have trended higher afterwards.
VLOPositive Net Change RMDNegative Net Change AEMPositive Net Change APPFNegative Net Change
basic-materials earnings gold inflation investing medical medical-devices oil-energy tech-stocks
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
NVOPositive Net Change LLYPositive Net Change CTLTPositive Net Change OMGAPositive Net Change
biotechnology earnings-preview medical
Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change AVTRPositive Net Change
earnings medical medical-devices
Sustained Product Demand Likely to Aid BD's (BDX) Q2 Earnings
by Zacks Equity Research
Continued solid uptake of BD's (BDX) products is expected to have driven fiscal second-quarter revenues.
BDXPositive Net Change UHSPositive Net Change THCPositive Net Change BPMCPositive Net Change
earnings medical medical-devices
Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.
ECLPositive Net Change BDXPositive Net Change ALGNNegative Net Change RVTYPositive Net Change
earnings medical medical-devices
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) third-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions segment.
CAHNegative Net Change EWNegative Net Change NVCRPositive Net Change SIBNPositive Net Change
medical medical-devices
How You Should Play Hologic (HOLX) Ahead of Q2 Earnings
by Riya Anand
Hologic's (HOLX) second-quarter 2024 earnings will likely reflect gains from the GYN surgical business and the growing adoption of Panther instruments.
HOLXPositive Net Change INSPPositive Net Change TMDXPositive Net Change HITINegative Net Change
earnings-preview medical medical-devices
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change SRPTPositive Net Change ARGXPositive Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid
by Zacks Equity Research
Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change BRKRPositive Net Change
medical
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
BAXPositive Net Change ZBHPositive Net Change LNTHPositive Net Change VERUNegative Net Change
medical medical-devices
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.
ECLPositive Net Change SYKPositive Net Change MMSIPositive Net Change NARINegative Net Change GEHCPositive Net Change
medical medical-devices
Amedisys (AMED) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Amedisys (AMED) tops on revenue and earnings estimates in the first quarter of fiscal 2024.
AMEDPositive Net Change HCAPositive Net Change EHCPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
by Santanu Roy
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
NVOPositive Net Change BMIPositive Net Change MUNegative Net Change TSCOPositive Net Change CLNegative Net Change SEPositive Net Change MKCPositive Net Change CSLNegative Net Change ALSNPositive Net Change ADMAPositive Net Change NOBLPositive Net Change BHKLYPositive Net Change
consumer-staples medical multi-sector-conglomerates
New Strong Buy Stocks for April 29th
by Zacks Equity Research
MHO, UHS, YOU, SPOT and AY have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2023.
UHSPositive Net Change MHOPositive Net Change AYNegative Net Change SPOTNegative Net Change YOUPositive Net Change
construction medical oil-energy
The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp
by Zacks Equity Research
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
BSXNegative Net Change LHPositive Net Change CAHNegative Net Change HOLXPositive Net Change TXGPositive Net Change
medical
Best Growth Stocks to Buy for April 29th
by Zacks Equity Research
AZZ, PDD and UHS made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 29, 2023.
UHSPositive Net Change AZZPositive Net Change PDDNegative Net Change
medical
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
ECLPositive Net Change PHGPositive Net Change BDXPositive Net Change IDXXPositive Net Change
medical medical-devices
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
CAHNegative Net Change EWNegative Net Change LNTHPositive Net Change SIBNPositive Net Change
medical medical-devices
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
ECLPositive Net Change UHSPositive Net Change THCPositive Net Change BPMCPositive Net Change
earnings medical medical-devices
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
LHPositive Net Change ALGNNegative Net Change RMDNegative Net Change ITGRPositive Net Change
earnings medical medical-devices
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYPositive Net Change SRPTPositive Net Change ARGXPositive Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Centene (CNC) Q1 Earnings Beat on Premiums, '24 EPS View Hiked
by Zacks Equity Research
Centene's (CNC) Q1 results reflect strength in the Commercial business line. Management currently expects adjusted EPS to be greater than $6.80 for 2024.
UHSPositive Net Change HUMNegative Net Change MOHPositive Net Change CNCNegative Net Change
earnings medical
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
BSXNegative Net Change LHPositive Net Change CAHNegative Net Change HOLXPositive Net Change TXGPositive Net Change
earnings medical medical-devices
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDNegative Net Change ANIPPositive Net Change SAGEPositive Net Change
biotechs medical pharmaceuticals